公开(公告)号：US20190247296A1

公开(公告)日：2019-08-15

申请号：US16329299

申请日：2017-09-05

Applicant: NOVA SOUTHEASTERN UNIVERSITY

Inventor： Mutasem Rawas-Qalaji ,  Rawan S. Bafail

IPC: A61K9/00 ,  A61K31/46 ,  A61K9/20 ,  A61K45/06 ,  A61P39/02

CPC classification number: A61K9/006 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2095 ,  A61K31/4425 ,  A61K31/46 ,  A61K31/5513 ,  A61K31/5517 ,  A61K45/06 ,  A61P39/02 ,  A61K2300/00

Abstract: The invention provides atropine sulfate (AS) rapidly-disintegrating sublingual tablets (RDSTs) of improved formulation in a sublingual dosage form and methods for therapeutic use of the AS RDSTs for treatment of organophosphate (OP) exposure and acute toxicity. The AS RDSTs provide an alternative easy-to-use dosage form for the management of organophosphate toxicity. Additionally, the invention provides methods for improved formulation and quality evaluation of the atropine sulfate rapidly-disintegrating sublingual tablets.

公开(公告)号：US20190125698A1

公开(公告)日：2019-05-02

申请号：US16225609

申请日：2018-12-19

Applicant: NOVA SOUTHEASTERN UNIVERSITY

Inventor： Mutasem RAWAS-QALAJI ,  Ousama RACHID ,  Keith SIMONS ,  Estelle SIMONS

IPC: A61K31/137 ,  A61K47/26 ,  A61K47/12 ,  A61K9/00 ,  A61K9/14 ,  A61K31/00

Abstract: The invention provides compositions including epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required.

公开(公告)号：US20180303824A1

公开(公告)日：2018-10-25

申请号：US15770193

申请日：2016-10-21

Applicant: NOVA SOUTHEASTERN UNIVERSITY

Inventor： Hossein Omidian ,  Srinath Muppalaneni ,  Yogesh N. Joshi ,  David J. Mastropietro

IPC: A61K31/485 ,  A61K31/135 ,  A61K9/20

CPC classification number: A61K31/485 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/135

Abstract: The invention enables the formation of prescription drugs less likely to be abused. Different approaches are employed that can potentially deter abuse by reducing the efficacy of main processes utilized by abusers to speed drug absorption and enhance its effect. Pharmaceutical compositions of the invention incorporate one or more of the following elements: super water-absorbency, alcohol absorption, organic binding agents, inorganic binding agents, adsorption, and tough platforms. These compositions function by preventing the isolation and concentration of drug constituents for misuse and/or preventing excessive intake. Thus, the invention encompasses various compositions and methods for reducing abuse of pharmaceutical products and alcohol.

公开(公告)号：US10070158B2

公开(公告)日：2018-09-04

申请号：US15505665

申请日：2015-08-21

Applicant: NOVA SOUTHEASTERN UNIVERSITY

Inventor： Abdelkrim Bourouihiya

IPC: H04N7/167 ,  H04N21/2347 ,  H04N19/46 ,  G06F17/16 ,  H04L9/30

Abstract: Digital files are compressed using a process including Schmidt decompositions of matrices using an algorithm, termed ‘BSD’ herein, which is based on an algebraic method generalizing QR decomposition. Software analyzes an input file and initially identifies a matrix M, with entries within a predefined set of integers, within the file. Next, essential entries are defined, extracted from M, that contain sufficient information to recover M using BSD. The compressed file includes the essential entries and their positions within M. To achieve an encryption process, software encrypts the pattern matrix that includes the positions of the essential entries of M. To achieve a lossy compression, software identifies essential entries that contain sufficient information to recover an approximation to M for which the quality is determined by an error threshold. For a more efficient lossy compression, software uses singular value decomposition, BSD, and other signal processing of M.

公开(公告)号：US20180147145A1

公开(公告)日：2018-05-31

申请号：US15882399

申请日：2018-01-29

Applicant: Nova Southeastern University

Inventor： Mutasem Rawas-Qalaji ,  Ousama Rachid ,  Keith Simons ,  Estelle Simons

IPC: A61K9/14 ,  A61K47/36 ,  A61K9/00 ,  A61K31/137 ,  A61K47/02

CPC classification number: A61K9/14 ,  A61K9/006 ,  A61K9/2054 ,  A61K9/5115 ,  A61K9/5161 ,  A61K31/137 ,  A61K31/194 ,  A61K47/02 ,  A61K47/36

Abstract: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.

公开(公告)号：US09877921B2

公开(公告)日：2018-01-30

申请号：US15266843

申请日：2016-09-15

Applicant: NOVA SOUTHEASTERN UNIVERSITY

Inventor： Mutasem Rawas-Qalaji ,  Ousama Rachid ,  Keith Simons ,  Estelle Simons

IPC: A61K9/16 ,  A61K9/14 ,  A61K9/00 ,  A61K31/137 ,  A61K47/36 ,  A61K47/02

CPC classification number: A61K31/137 ,  A61K9/006 ,  A61K9/2054 ,  A61K9/5161

Abstract: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.

公开(公告)号：US20170071881A1

公开(公告)日：2017-03-16

申请号：US15358743

申请日：2016-11-22

Applicant: NOVA SOUTHEASTERN UNIVERSITY

Inventor： Mutasem RAWAS-QALAJI ,  Ousama RACHID ,  Keith John SIMONS ,  Estelle SIMONS ,  Enrique NIEVES

IPC: A61K31/137 ,  A61K9/19 ,  A61K9/00

Abstract: The invention provides a composition including epinephrine nanoparticles and methods for therapeutic use of the composition in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.

Abstract translation: 本发明提供了包含肾上腺素纳米颗粒的组合物和用于治疗使用该组合物治疗对肾上腺素（例如心脏事件或过敏反应，特别是过敏反应）的病症的方法。 肾上腺素纳米颗粒可以掺入到口腔崩解和快速崩解片剂药物制剂中，并且可以显着增加肾上腺素的舌下生物利用度，从而降低所需的肾上腺素剂量。 另外，本发明提供了用于制备用于所述组合物的稳定的肾上腺素纳米颗粒的方法。

公开(公告)号：US20160275236A1

公开(公告)日：2016-09-22

申请号：US15028757

申请日：2014-10-14

Applicant: NOVA SOUTHEASTERN UNIVERSITY

Inventor： Mary Ann FLETCHER ,  Gordan BRODERICK ,  Nancy KLIMAS ,  Zachary BARNES

IPC: G06F19/12 ,  A61K38/20

CPC classification number: G16B5/00 ,  A61K38/2086 ,  G16B40/00

Abstract: A general method of analyzing immune signaling networks for identification of potential therapeutic targets in complex, chronic medical disorders is described. The disclosure provides the CD3−/CD56+ natural killer (NK) cell population as a potential therapeutic target in the clinically-overlapping disorders Gulf War Illness (GWI) and Myalg Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The disclosure also provides a method for improving or restoring Natural Killer (NK) cell function by stimulating the NK cells with interleukin-15 (IL-15).

Abstract translation: 描述了分析用于鉴定复杂，慢性医学病症中的潜在治疗靶标的免疫信号网络的一般方法。 本公开提供了CD3 / CD56 +自然杀伤（NK）细胞群作为临床重叠疾病海湾病（GWI）和Myalg脑脊髓炎/慢性疲劳综合征（ME / CFS）的潜在治疗靶点。 本公开还提供了通过用白细胞介素-15（IL-15）刺激NK细胞来改善或恢复天然杀伤（NK）细胞功能的方法。

公开(公告)号：US20160045457A1

公开(公告)日：2016-02-18

申请号：US14778887

申请日：2014-03-24

Applicant: Ousama RACHID ,  Keith SIMONS ,  Estelle SIMONS ,  NOVA SOUTHEASTERN UNIVERSITY

Inventor： Mutasem RAWAS-QALAJI ,  Ousama RACHID ,  Keith SIMONS ,  Estelle SIMONS

IPC: A61K31/137 ,  A61K9/00

CPC classification number: A61K31/137 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/14 ,  A61K31/00 ,  A61K47/12 ,  A61K47/26

Abstract: The invention provides compositions including epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required.

Abstract translation: 本发明提供了包括肾上腺素细颗粒，包括肾上腺素纳米颗粒或纳米晶体和肾上腺素微粒或微晶的组合物，以及用于治疗使用该组合物治疗对肾上腺素（例如心脏事件或过敏反应特别是过敏反应）的病症的方法。 肾上腺素细颗粒可以掺入口腔崩解和快速崩解片剂药物制剂中，并可显着增加肾上腺素的舌下生物利用度，从而降低所需的肾上腺素剂量。

公开(公告)号：US20140314890A1

公开(公告)日：2014-10-23

申请号：US14354939

申请日：2012-10-30

Applicant: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES ,  NOVA SOUTHEASTERN UNIVERSITY

Inventor： Miroslav Gantar ,  Appu Rathinavelu ,  Sivanesan Dhandayuthapani

IPC: A61K35/74 ,  A61K45/06 ,  A61K38/16

CPC classification number: A61K35/748 ,  A61K31/175 ,  A61K31/337 ,  A61K31/407 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/555 ,  A61K31/675 ,  A61K31/704 ,  A61K33/24 ,  A61K38/164 ,  A61K45/06 ,  A61K2300/00

Abstract: Discloses herein is a combination therapy for treating cancer by administration of a phycocyanin and a chemotherapeutic.

Abstract translation: 本文公开了通过施用藻蓝蛋白和化学治疗来治疗癌症的组合疗法。